NCT03878823View on ClinicalTrials.gov

Safety and Pharmacokinetics of ODM-209

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions
Prostate Cancer MetastaticAdvanced Breast CancerCastration-resistant Prostate CancerMetastatic Breast Cancer
Interventions
DRUG

ODM-209

co-administered with glucocorticoid and mineralocorticoid, orally daily

Trial Locations (4)

Unknown

Rigshospitalet, University Hospital of Copenhagen, Copenhagen

Helsinki University Central Hospital, Helsinki

Tampere University Hospital, Tampere

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

Orion Corporation, Orion Pharma

INDUSTRY

NCT03878823 - Safety and Pharmacokinetics of ODM-209 | Biotech Hunter | Biotech Hunter